These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 3899662

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Metabolism of vincamine in the rat].
    Viganò V, Paracchini S, Piacenza G, Pesce E.
    Farmaco Sci; 1978 Aug; 33(8):583-94. PubMed ID: 744256
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metabolism of vincamine in the rat in vivo and in vitro.
    Vereczkey L, Tamás J, Czira G, Szporny L.
    Arzneimittelforschung; 1980 Aug; 30(11):1860-5. PubMed ID: 7192994
    [Abstract] [Full Text] [Related]

  • 7. In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine.
    Fandy TE, Abdallah I, Khayat M, Colby DA, Hassan HE.
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):259-67. PubMed ID: 26666648
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects.
    Millart H, Lamiable D, Houin G, Plat M, Choisy H, Tillement JP.
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):581-6. PubMed ID: 6654533
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biopharmaceutic and pharmacokinetic aspects of vincamine HCl.
    Ritschel WA, Agrawala P.
    Methods Find Exp Clin Pharmacol; 1985 Mar; 7(3):129-36. PubMed ID: 4010386
    [Abstract] [Full Text] [Related]

  • 13. [Relative bioavailability of a vincamine retard formulation. Pharmacokinetic study in normal subjects (author's transl)].
    Erking W, Lücker PW, Metz G, Specker M, Wetzelsberger K.
    Arzneimittelforschung; 1978 Mar; 28(12):2332-6. PubMed ID: 582951
    [Abstract] [Full Text] [Related]

  • 14. The metabolic fate of 11-bromo-[15-3H] vincamine in rats, dogs and humans.
    Mayo BC, Biggs SR, Hawkins DR, Chasseaud LF, Darragh A, Baldock GA, Whitby BR.
    J Pharmacobiodyn; 1982 Dec; 5(12):951-64. PubMed ID: 7169608
    [No Abstract] [Full Text] [Related]

  • 15. Studies on the vincamine-papaverine association. i. biochemical investigations.
    Costrini R, Galzigna L, Bianchi M, Nunziata A, Cattani L.
    Agressologie; 1978 Dec; 19(3):211-4. PubMed ID: 736220
    [No Abstract] [Full Text] [Related]

  • 16. Eburnamine derivatives and the brain.
    Vas A, Gulyás B.
    Med Res Rev; 2005 Nov; 25(6):737-57. PubMed ID: 16158388
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Autoradiographic evidence for passage of vincamine through the blood-brain barrier.
    Sprumont P, Lintermans J.
    Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):42-8. PubMed ID: 485685
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of vinpocetine in humans.
    Vereczkey L, Czira G, Tamás J, Szentirmay Z, Botár Z, Szporny L.
    Arzneimittelforschung; 1979 Jan; 29(6):957-60. PubMed ID: 582791
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.